Loading the company…
Loading the company…
Families: Lumbar fusion, Bone graft & orthobiologics.
All companies · Product and company coverage
In the last ten years FDA made 13 decisions for Kuros Biosciences (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2024 (3). The latest was on 2025-05-23.
| Family | Decisions on record |
|---|---|
| Lumbar fusion | 13 |
| Bone graft & orthobiologics | 12 |
In 2025, Kuros Biosciences reported engagement with 687 surgeons and other clinicians in the states MedaRep covers, worth $1.2M in consulting, speaking, meals and travel for its device products, the most in California ($138K to 48). Royalties are left out.
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Kuros Biosciences.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($138K, 48 engaged), Ohio ($123K, 32 engaged), Pennsylvania ($91K, 90 engaged), Illinois ($76K, 37 engaged), Texas ($74K, 41 engaged).